Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q99973

UPID:
TEP1_HUMAN

ALTERNATIVE NAMES:
Telomerase-associated protein 1; p240; p80 telomerase homolog

ALTERNATIVE UPACC:
Q99973; A0AUV9

BACKGROUND:
The Telomerase protein component 1, known alternatively as Telomerase-associated protein 1, p240, and p80 telomerase homolog, is integral to the replication of chromosome ends and cellular longevity. This protein is part of the telomerase complex and the ribonucleoprotein vaults particle, indicating its multifaceted role in genomic stability and intracellular transport. Its binding to TERC underscores its significance in telomere maintenance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Telomerase protein component 1 unveils potential avenues for therapeutic intervention. Given its critical role in telomere maintenance and genomic stability, targeting this protein could lead to breakthroughs in treating age-related disorders and cancers.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.